Format

Send to

Choose Destination
Nat Rev Neurol. 2015 Jan;11(1):41-55. doi: 10.1038/nrneurol.2014.232. Epub 2014 Dec 16.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Author information

1
Department of Neurology, Institut d'Investigacions Biomèdiques, Hospital de Sant Pau, Sant Antoni Maria, Claret 167, Barcelona 08025, Spain.
2
IRCCS Istituto Centro San Giovanni di Dio-Fatebenefratelli, Italy.
3
Ospedale Santa Maria della Misericordia, Università di Perugia, Italy.
4
ADxNeurosciences, Belgium.
5
University of Eastern Finland and Kuopio University Hospital, Finland.
6
Karolinska Institute, Sweden.
7
Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
8
Quanterix, USA.
9
Aristotle University of Thessaloniki, Greece.
10
Medical University of Białystok, Poland.
11
Maastricht University, Netherlands.
12
University of Coimbra, Portugal.
13
The Sahlgrenska Academy at University of Gothenburg, Sweden.
14
Stavanger University Hospital, Norway.
15
ICN Hospital Clinic i Universitari, IDIBAPS, Spain.
16
Paracelsus-Elena-Klinik, Germany.

Abstract

Alzheimer disease (AD) and Parkinson disease (PD) are the most common neurodegenerative disorders. For both diseases, early intervention is thought to be essential to the success of disease-modifying treatments. Cerebrospinal fluid (CSF) can reflect some of the pathophysiological changes that occur in the brain, and the number of CSF biomarkers under investigation in neurodegenerative conditions has grown rapidly in the past 20 years. In AD, CSF biomarkers are increasingly being used in clinical practice, and have been incorporated into the majority of clinical trials to demonstrate target engagement, to enrich or stratify patient groups, and to find evidence of disease modification. In PD, CSF biomarkers have not yet reached the clinic, but are being studied in patients with parkinsonism, and are being used in clinical trials either to monitor progression or to demonstrate target engagement and downstream effects of drugs. CSF biomarkers might also serve as surrogate markers of clinical benefit after a specific therapeutic intervention, although additional data are required. It is anticipated that CSF biomarkers will have an important role in trials aimed at disease modification in the near future. In this Review, we provide an overview of CSF biomarkers in AD and PD, and discuss their role in clinical trials.

PMID:
25511894
DOI:
10.1038/nrneurol.2014.232
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center